Genetic biliary tract disease

Genetic biliary tract disease is a broad classification term used by Orphanet (ORPHA:156607) to group a heterogeneous collection of rare inherited disorders that primarily affect the biliary system — the network of bile ducts that transport bile from the liver to the gallbladder and small intestine. This category encompasses a range of conditions including progressive familial intrahepatic cholestasis (PFIC) syndromes, Alagille syndrome, Caroli disease, choledochal cysts of genetic origin, and other hereditary cholangiopathies. These disorders share the common feature of impaired bile formation, bile flow, or structural abnormalities of the bile ducts due to underlying genetic mutations. The clinical manifestations vary widely depending on the specific condition but commonly include cholestasis (reduced or absent bile flow), jaundice (yellowing of the skin and eyes), pruritus (intense itching), hepatomegaly (enlarged liver), failure to thrive in children, fat-soluble vitamin deficiencies, and progressive liver fibrosis or cirrhosis. Some conditions within this group may also affect the kidneys, heart, skeleton, or eyes, depending on the gene involved. Onset can range from the neonatal period to adulthood. Because this is a grouping category rather than a single disease entity, treatment approaches vary considerably. Management may include ursodeoxycholic acid to improve bile flow, surgical interventions such as biliary diversion procedures, nutritional supplementation of fat-soluble vitamins, and in severe cases, liver transplantation. Genetic testing and counseling are essential for accurate diagnosis and family planning. Patients are encouraged to seek care at specialized hepatology or genetics centers familiar with these rare conditions.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Genetic biliary tract disease